Contents
On this page
- Limitations of announcing GPP as a means of adoption
- Evidence on adoption from reporting guidelines
- Four mechanisms of adoption and their capabilities
- Drafting operable standard operating procedure clauses
- Effective contract clauses
- Design of the publication approval gate
- Formulating an accurate internal business case
- The importance of the external community
- Assessing whether adoption has occurred
- Key points
- Application to your study
- Frequently asked questions
Academy · Research Publication · Promoting GPP internally
Organisational Adoption of Good Publication Practice (GPP): Procedures, Contracts and Approval Gates
Circulating Good Publication Practice (GPP) guidance does not constitute its adoption. GPP is adopted when it is incorporated into a standard operating procedure (SOP) that names a decision owner, into contracts with agencies and investigators, and into an approval gate that a publication cannot pass without meeting its requirements. Other measures raise awareness, and awareness alone tends not to withstand deadline pressure.
The principal difficulty in implementing GPP is not understanding the guideline but the absence of external enforcement for most of its requirements. A journal checks authorship and registration, but no external party can verify whether a written agreement existed before drafting, whether authors had adequate review time, or whether a completed study was never written up. Adoption must therefore be constructed within the organisation rather than announced. This article examines how such adoption can be achieved.
Learning objectives
- Why distributing the guideline, holding a briefing session and adding a policy statement consistently fail to achieve adoption
- The four mechanisms that change behaviour: SOP, contract, gate, training — and what each can and cannot achieve
- Which clauses in an agency statement of work are effective, and the wording that makes them operable
- How to design a publication approval gate that identifies the upstream GPP requirements that a journal cannot observe
- The evidence that can legitimately support the internal case, including the Gattrell reporting-quality findings
- What to measure after six months to determine whether adoption has occurred or has merely been declared
Common misconceptions
- “GPP has been adopted because it is named in the publication policy.” A policy statement without a named owner, an approval gate or contract language is a statement of intent. The relevant test is who can block a publication for non-compliance; if no one can, GPP has not been adopted.
- “Training is the principal mechanism.” Training conveys what should be done but does not ensure that it is done under deadline pressure. The effective mechanism is an approval gate that a publication cannot pass without compliance.
- “The agency will ensure GPP compliance.” Agencies work to the standard that the statement of work (SOW) specifies. An SOW requiring work “in accordance with applicable guidelines” specifies no standard.
- “This is a medical affairs matter, not a legal or procurement matter.” The written agreement, the data-control clause and the publication-veto terms are all contained in contracts. Without the involvement of procurement and legal functions, the most consequential GPP requirement is unenforceable.
- “The absence of complaints indicates that adoption is effective.” The GPP failures with the most serious consequences, such as non-publication and retrospectively altered author lists, generate no complaints. The absence of complaints is therefore not evidence of adoption.
Limitations of announcing GPP as a means of adoption
The standard rollout comprises a policy update, an email with the guideline attached, a webinar, and a slide in the onboarding materials. Six months later, publications are still being drafted before anyone has documented who controls the data, author lists are still being assembled from a stakeholder map rather than on the basis of contribution, and congress abstracts are still being submitted without the writer declared.
This is not a failure of goodwill but a structural problem. The requirements of GPP fall into two distinct groups: those that a journal checks at submission, and those that are not visible to anyone outside the organisation. The first group — authorship criteria, acknowledgements, funding disclosure, trial registration — is generally completed, because a submission form prompts it and a rejection penalises its absence 1. The second group — written agreements, publication plans, meaningful author review, and the publication of studies that should be published — has neither prompt nor penalty 10,15. Under deadline pressure, requirements without enforcement consistently yield to requirements with enforcement, regardless of the content of any training.
Adoption therefore requires the missing enforcement to be created internally. There are four means of achieving this, and they are not equally effective. The requirements themselves are set out on what GPP3 requires in practice; this page assumes familiarity with them and addresses their implementation.
Evidence on adoption from reporting guidelines
There is no published trial of GPP implementation. There is, however, a relevant parallel literature on the uptake of reporting guidelines, and its conclusion is consistent: guidelines change behaviour when a gatekeeper requires them, and have limited effect otherwise 11,12.
Turner and colleagues’ Cochrane review, in Systematic Reviews, examined whether use of the CONSORT statement improves the completeness of randomised trial reporting, and found the evidence for improvement associated with journal endorsement to be real but limited and of mixed quality 11. Hopewell and colleagues, in BMJ, examined a more stringent case: an interrupted time series of changes in abstract reporting in high-impact journals when editors actively implemented the CONSORT extension for abstracts — that is, when compliance became a condition of passing the editorial gate rather than a recommendation in the instructions 12,20.
The transferable conclusion concerns mechanism, not magnitude. Passive endorsement produces modest change; active implementation at a decision point produces more 12. The internal equivalent of the editor’s gate is the publication approval step, and if GPP is not checked at that step, it is only being passively endorsed.
Four mechanisms of adoption and their capabilities
The SOP defines what must happen and who owns each decision. Its function is to remove ambiguity, not to educate. An SOP stating that publications “should follow GPP” achieves nothing; an SOP stating that the written agreement must be signed by the sponsor lead, the lead author and the agency before the outline is drafted, and naming the role that approves it, is effective.
The contract binds the parties that the SOP cannot reach — agencies, external investigators, CROs. It is the only mechanism that applies to people who do not report to the organisation, and it is the one most often left as boilerplate.
The gate is the enforcement mechanism. A publication cannot proceed beyond a defined point without evidence that the upstream requirements have been met. This mechanism gives effect to the other three, and it is the one organisations are most reluctant to establish, because it slows the process and creates a named person who must be able to refuse approval.
Training builds the capability to do what the other three require. It is necessary but not sufficient. Training without a gate produces staff who know that they are omitting a requirement, which is not the same as staff who do not omit it.
Where only one mechanism can be established in a given year, it should be the gate, which will then reveal which SOP clauses and contract terms are missing. Programme-level governance structures are covered on publication governance, and sequencing on publication planning.
The four adoption levers compared
| Lever | What it can do | What it cannot do | Who has to be involved |
|---|---|---|---|
| SOP | Remove ambiguity; name decision owners; require filed artefacts | Bind anyone outside the organisation; survive deadline pressure on its own | Medical affairs, quality, document owner |
| Contract / SOW | Bind agencies, investigators and CROs; fix the standard and the version | Reach internal behaviour, or anything not written into it | Procurement, legal, publication lead |
| Gate | Convert requirements into conditions of progress; generate the evidence base | Function if the person under pressure can waive it | A named approver with authority to say no |
| Training | Build capability; explain why; reduce honest mistakes | Change behaviour where omitting a requirement is rewarded | Everyone drafting, reviewing or approving |
This is a Pubrica framework, not a GPP recommendation. The mechanism argument — that active implementation at a decision point outperforms passive endorsement — is drawn from the reporting-guideline uptake literature, including Turner and colleagues’ Cochrane review in Systematic Reviews and Hopewell and colleagues’ interrupted time series in BMJ.
Drafting operable standard operating procedure clauses
An operable clause has four properties: a trigger (when it applies), an action (what must exist), an owner (who is accountable), and an artefact (what is filed as evidence). Most GPP SOP clauses lack the last two.
Author selection provides an example. “Authorship will be determined in accordance with ICMJE criteria” is unenforceable because no artefact is produced and no owner is named. “Before the outline is circulated, the publication lead will complete the authorship grid, recording each proposed author against each ICMJE criterion, and will file it in the publication record; contributors not meeting all criteria are entered on the acknowledgements list at the same time” is enforceable, because an auditor can request the grid and verify whether it exists.
The same test applies to every GPP topic that an organisation seeks to embed. If a clause does not generate a filed artefact, compliance cannot be verified, and it is therefore unlikely to occur. The disclosure topics that most require supporting artefacts are listed on the GPP topics authors most often miss.
An agency statement-of-work clause, as usually written and as it should read
Unenforceable
The Supplier shall provide medical writing services in accordance with applicable industry guidelines and good publication practice. The Supplier shall ensure that all publications comply with relevant ethical standards. Acknowledgement of the Supplier’s contribution shall be made where appropriate.
“Applicable industry guidelines” names nothing. It can be satisfied by any document, including none.
“Where appropriate” hands the attribution decision to whoever is least comfortable with it.
No trigger. Nothing prevents drafting from starting before the written agreement exists — the most common GPP failure.
Congress abstracts are not mentioned, so the output most often under-declared is out of scope.
No escalation route. An agency that identifies a problem can raise it only with the person responsible for it.
Operable
The Supplier shall provide medical writing services in accordance with GPP 2022 (DeTora et al., Annals of Internal Medicine 2022;175:1298–1304), the current ICMJE Recommendations, and the reporting guideline applicable to each study design, as specified in the publication-specific work order. For every output, including congress abstracts and posters, the Supplier shall require that its contribution be declared by named individual, employer and funder, and shall decline to finalise any output where the author group will not permit that declaration. The Supplier shall not commence outlining or drafting until the Sponsor has provided (a) the signed written agreement for that publication and (b) the completed authorship grid. Where the Supplier believes a requirement of the named standards is being breached, it shall notify the Sponsor’s publication governance lead in writing within five working days; raising such a notice shall not constitute a performance deficiency under this Agreement.
The standard, its version and its citation are fixed, so compliance is a checkable question.
Attribution is specified down to individual, employer and funder, and across every output type.
The agency is contractually required to refuse, which removes the commercial pressure to accommodate a client who wishes the writer to remain undisclosed.
Drafting is gated on two named artefacts, which makes the upstream requirement enforceable by someone other than the sponsor.
Escalation has a recipient, a deadline and protection — the three conditions that make a concern reportable in practice.
Nothing in the second version is onerous for a competent agency; most agencies are likely to welcome the attribution and escalation clauses, because they remove a negotiation that agencies currently tend to lose. The change is from a clause that expresses an intention to one that produces artefacts and permits refusal, which is the decisive difference when a deadline arrives.
Effective contract clauses
Three clauses are of primary importance in an agency statement of work or a master service agreement, and all three are commonly written as boilerplate.
Standards clause. The document and the version should be named — GPP 2022, published by DeTora and colleagues in Annals of Internal Medicine, or GPP3 if that is the version the organisation’s SOPs still reference — together with the ICMJE Recommendations and the relevant reporting guideline 1,6. “Applicable industry guidelines” names nothing and can be satisfied by anything.
Attribution clause. The agency’s contribution should be required to be declared by named individual, employer and funder in every output, including congress abstracts and posters, and the agency should be required to refuse to proceed if an author group declines to make that declaration. The second requirement is the essential one; without it, the agency must choose between the clause and the client.
Escalation clause. The clause should specify what the agency must do when it believes a GPP requirement is being breached — whom it notifies, within what timeframe, and that doing so does not constitute a performance issue. An agency that can raise a concern only with the person creating the problem is unlikely to raise it.
A further clause is required for investigator and CRO contracts: a publication clause that states the obligation to publish irrespective of the direction of results, with a maximum permitted delay and the grounds for it. Antes and Chalmers set out the underlying case in the Lancet: under-reporting of clinical trials is unethical, and non-publication is the GPP failure with no external check at all 32.
Design of the publication approval gate
A gate is a point at which a publication cannot advance without named evidence. Two gates are sufficient for most organisations, and more than two tend to become a formality.
Gate one, before drafting. Evidence required: signed written agreement; completed authorship grid; registration status confirmed with dates; the paper’s place in the publication plan, including its relationship to the primary report. None of these depends on the existence of a draft, which is intentional — these are the requirements that cannot be satisfied with integrity at a later stage.
Gate two, before submission. Evidence required: final authorship grid, unchanged or with changes explained; complete acknowledgement block with permissions on file; sponsor-role and data-access statements drafted; prior disclosure inventory, including congress abstracts and preprints; reporting-guideline checklist completed; similarity report reviewed.
Two design decisions determine whether the gate is effective. The first is who can waive it: if the person under deadline pressure can waive it, it is not a gate. The second is the cost of the gate. A gate that takes two weeks will be circumvented; a gate that consists of a half-hour review against a filed checklist will not. The evidence requirements should be limited to artefacts that already exist at that point in the process, which is why the SOP clauses must generate artefacts.
Formulating an accurate internal business case
Those responsible for adoption will be asked to justify its value. There is a defensible case and there is an overclaim, and relying on the overclaim will damage credibility as soon as it is examined.
The defensible case has three parts. Avoided rework and rejection: authorship disputes, missing registration, undeclared prior presentation and redundancy queries all generate rework that is considerably more costly than the gate. Reporting quality: Gattrell and colleagues, in BMJ Open, found that among 233 randomised controlled trial reports, 39.1% — 43 of 110 — of those with declared professional medical writing support completely reported at least half the assessed CONSORT items, against 21.1% (26 of 123) without support, an adjusted odds ratio of 1.88 (95% CI 1.03 to 3.42) 8. The same study found peer reviewers judged the written English acceptable in 81.1% of articles with writing support against 47.9% without 8. Defensibility: the programme-level records that a GPP process generates are the only available evidence if the publication practice is ever questioned.
The overclaim to avoid is that GPP adherence improves acceptance, impact or the trustworthiness of the literature. None of these effects has been demonstrated. The Gattrell findings are cross-sectional associations concerning writing support, not GPP compliance, and the confidence interval for the CONSORT result approaches 1 7,8. Stating this explicitly preserves credibility under critical scrutiny.
The importance of the external community
One further mechanism lies outside the organisation and is inexpensive to use: the professional community that maintains the guideline. GPP 2022 was developed through a broad consultation — 38 invited experts gave feedback before submission, and an open reviewer call returned more than 120 sets of comments, representing the input of hundreds of professionals 5,6. ISMPP had more than 2,200 members at the time it was published, and the guideline itself appeared in Annals of Internal Medicine, volume 175, issue 9, pages 1298 to 1304, published online on 30 August 2022 5,6.
This is relevant to internal adoption in a practical way. When a colleague argues that GPP is one vendor’s opinion, the scale of the consultation provides the response, and the Annals citation answers the question of its provenance. It is also relevant to the organisation’s own staff: a publication team with external professional membership tends to regard GPP not as an internal compliance burden but as the standard of its own field, which is a considerably more durable motivation than an SOP.
The GPP 2022 consultation. Source: International Society for Medical Publication Professionals announcement of the publication of GPP 2022 in Annals of Internal Medicine.
Assessing whether adoption has occurred
Metrics should be derived from artefacts, not from surveys of whether staff consider themselves compliant. Five metrics are sufficient.
The proportion of publications with a signed written agreement dated before the outline. The proportion with an authorship grid completed before drafting, and the proportion where the author list changed after the grid was filed, with reasons. The proportion of congress abstracts declaring writing support by named individual and funder — abstracts, because they are the output most often managed to a lower standard. The number of publications that cleared the gate with a waiver, and who signed each waiver. And the number of completed studies in the portfolio with no publication plan, reviewed quarterly.
The last metric is the only one that addresses the GPP failure with no external check, and it is the one most likely to be resisted. Placing a quarterly count of completed but unpublished studies on a governance agenda, and keeping it there, will achieve more than any amount of training.
The first set of figures is likely to be unfavourable. This is informative rather than embarrassing: a demonstrable baseline is what converts GPP adoption from an opinion into a project.
Key points
Key points
GPP is adopted through documented artefacts and approval gates rather than through awareness. Requirements that journals check are enforced externally; those of greatest importance, namely written agreements, appropriate authorship decisions, adequate review time and the publication of studies that should be published, have no external enforcement, and the organisation must therefore provide it. Organisations should establish two approval gates with specified evidence, ensure that SOP clauses generate filed artefacts, name the standard and its version in every contract, and measure five indicators from those artefacts. The internal case should rest on avoided rework and defensibility, and should not claim that GPP improves acceptance or impact, because no evidence has demonstrated this.
Application to your study
Application to your study
- The content of existing organisational documents should be established. SOPs and master agreements should be searched for references to GPP, and the version named, if any, recorded. A reference to “applicable guidelines” should be treated as naming no standard.
- It should be established who has authority to stop a publication for GPP non-compliance. If no role has this authority, the organisation has a policy rather than an adoption, and this finding should be reported.
- One SOP clause should be revised so that it produces a filed artefact. The authorship grid is a suitable starting point, specifying trigger, action, owner and artefact. The clause should be audited after one month by requesting three completed grids.
- An approval gate should be placed before drafting as well as before submission. The gate should require the signed written agreement and the completed authorship grid. No other measure identifies these upstream failures.
- The standards, attribution and escalation clauses should be revised in the next agency SOW. The SOW should name the version with its citation, require declaration by named individual and funder in every output including abstracts, and specify a recipient and a deadline for escalation.
- Authority to waive the gate should be assigned to a person not subject to the relevant deadline. Every waiver should be logged with the name of the signatory.
- Baseline values for five metrics should be established from artefacts in the current quarter, including the number of completed studies without a publication plan. Unfavourable values should be anticipated and nonetheless reported.
- An accurate business case should be presented in writing. The case should rest on avoided rework, reporting quality as indicated by the Gattrell data with its limitations stated, and defensibility. No benefit to acceptance or impact should be claimed.
Frequently asked questions
A gate should be placed before drafting that requires two artefacts: the signed written agreement for that publication, and the completed authorship grid. Every other GPP requirement is either prompted by a journal submission form or depends on the existence of those two documents. A gate at submission is useful but too late for the upstream requirements, because by then the result is known and the author list has become difficult to change. The reason to begin with a gate rather than an SOP revision is that the gate immediately reveals which SOP clauses and contract terms are missing, and so performs the analysis itself.
Three arguments are defensible. Avoided rework: authorship disputes, missing registration, undeclared prior presentation and redundancy queries all cost considerably more than the gate. Reporting quality: Gattrell and colleagues, in BMJ Open, found 39.1% of 110 trial reports with declared writing support completely reported at least half the assessed CONSORT items against 21.1% of 123 without, an adjusted odds ratio of 1.88 (95% CI 1.03 to 3.42), and reviewers judged the English acceptable in 81.1% versus 47.9%. Defensibility: the records a GPP process generates are the evidence on which the organisation will rely if its practice is challenged. Improved acceptance, impact or credibility should not be claimed, because these have not been demonstrated.
Three clauses. A standards clause naming the document and version — GPP 2022, published by DeTora and colleagues in Annals of Internal Medicine, or GPP3 if the organisation’s SOPs still cite it — together with the ICMJE Recommendations and the applicable reporting guideline. An attribution clause requiring declaration by named individual, employer and funder in every output, including congress abstracts, and obliging the agency to decline where the author group refuses that declaration. An escalation clause naming whom the agency notifies about a suspected breach, within what period, with explicit protection against its being treated as a performance issue.
It is necessary but insufficient. Training reduces honest mistakes and builds the capability to produce the artefacts an SOP requires, but it does not change behaviour where omitting a requirement is rewarded and nothing prevents it. The closest available evidence comes from the reporting-guideline literature rather than from GPP: Turner and colleagues’ Cochrane review in Systematic Reviews found the effect of passive guideline endorsement limited, while Hopewell and colleagues in BMJ examined the effect when editors actively implemented a guideline as a condition of progress. Training should be combined with a gate, and training alone should be regarded as awareness-raising.
It should be treated as a contractual question rather than a matter of persuasion, which is the purpose of the attribution clause. Where argument is required, the position is that disclosure is the norm and concealment is the risk: undisclosed substantive contribution constitutes ghostwriting, which creates the reputational exposure, whereas declared support is permitted under GPP and, in Gattrell and colleagues’ data, associated with more complete rather than less complete CONSORT reporting. Vague wording such as “editorial assistance was provided” is the least satisfactory option, because it signals concealment without achieving it.
Five metrics, all derived from artefacts rather than surveys. The proportion of publications with a signed written agreement dated before the outline. The proportion with an authorship grid completed before drafting, together with how often the list changed afterwards and why. The proportion of congress abstracts declaring writing support by named individual and funder. The number of gate waivers and the signatory of each. A quarterly count of completed studies with no publication plan — the only metric that addresses the GPP failure that no journal can detect. The first baseline is likely to be unfavourable; that is what makes adoption a project rather than an opinion.
GPP 2022 should be named in any new SOP or contract: it is the current version in the lineage, published by DeTora and colleagues in Annals of Internal Medicine, volume 175, issue 9, pages 1298 to 1304, online on 30 August 2022. Where legacy SOPs and master agreements still name GPP3, the organisation faces a transition problem rather than a choice — the contracted standard is whatever the signed document states, so the documents should either be amended or GPP3 accepted as the operative standard for those programmes. Naming neither version, or naming “good publication practice” generically, is ineffective.
A named role with authority to stop a publication, positioned outside the team under deadline pressure — typically a publication governance lead in medical affairs, with quality owning the SOP and procurement and legal owning the contract clauses. Ownership divided across a committee with no individual approver consistently produces a gate that can be waived informally. The critical test is not the position of the role on the organisational chart but whether that person’s objection must be formally overridden by a senior colleague, and whether that override is logged.
References
- International Committee of Medical Journal Editors. Recommendations for the Conduct, Reporting, Editing, and Publication of Scholarly Work in Medical Journals. ICMJE. 2026. read 9 October 2026. icmje.org
- Committee on Publication Ethics. Text recycling guidelines. COPE. 2013. read 9 October 2026. par.nsf.gov
- International Committee of Medical Journal Editors. The New ICMJE Recommendations (August 2013). ICMJE. 2013. read 9 October 2026. icmje.org
- Committee on Publication Ethics. Core Practices. COPE. read 9 October 2026. equator-network.org
- International Society for Medical Publication Professionals. GPP 2022: Good Publication Practice guidelines for company-sponsored biomedical research published in Annals of Internal Medicine (press release). ISMPP. 2022. read 9 October 2026. ismpp.org
- DeTora LM, Toroser D, Sykes A, Vanderlinden C, Plunkett FJ, Lane T, Hanekamp E, Dormer L, DiBiasi F, Bridges D, Baltzer L, Citrome L. Good Publication Practice (GPP) Guidelines for Company-Sponsored Biomedical Research: 2022 Update. Annals of Internal Medicine. 2022;175(9):1298-1304. doi:10.7326/M22-1460 read 9 October 2026. doi.org/10.7326/M22-1460
- Mills I, Sheard C, Hays M, Douglas K, Winchester CC, Gattrell WT. Professional medical writing support and the reporting quality of randomized controlled trial abstracts among high-impact general medical journals. F1000Research. 2017;6:1489. doi:10.12688/f1000research.12268.2 read 9 October 2026. doi.org/10.12688/f1000research.12268.2
- Gattrell WT, Hopewell S, Young K, Farrow P, White R, Wager E, Winchester CC. Professional medical writing support and the quality of randomised controlled trial reporting: a cross-sectional study. BMJ Open. 2016;6(2):e010329. doi:10.1136/bmjopen-2015-010329 read 9 October 2026. doi.org/10.1136/bmjopen-2015-010329
- Roig M; US Office of Research Integrity. Avoiding plagiarism, self-plagiarism, and other questionable writing practices: a guide to ethical writing. US Office of Research Integrity. 2015. read 9 October 2026. equator-network.org
- Battisti WP, Wager E, Baltzer L, Bridges D, Cairns A, Carswell CI, Citrome L, Gurr JA, Mooney LA, Moore BJ, Pena T, Sanes-Miller CH, Veitch K, Woolley KL, Yarker YE. Good Publication Practice for Communicating Company-Sponsored Medical Research: GPP3. Annals of Internal Medicine. 2015;163(6):461-464. doi:10.7326/M15-0288 read 9 October 2026. doi.org/10.7326/M15-0288
- Turner L, Shamseer L, Altman DG, Schulz KF, Moher D. Does use of the CONSORT statement impact the completeness of reporting of randomised controlled trials published in medical journals? A Cochrane review. Systematic Reviews. 2012;1:60. read 9 October 2026. care-statement.org
- Hopewell S, Ravaud P, Baron G, Boutron I. Effect of editors' implementation of CONSORT guidelines on the reporting of abstracts in high impact medical journals: interrupted time series analysis. BMJ. 2012;344:e4178. read 9 October 2026. care-statement.org
- Wislar JS, Flanagin A, Fontanarosa PB, et al. Honorary and ghost authorship in high impact biomedical journals: a cross sectional survey. BMJ. 2011;343:d6128. doi:10.1136/bmj.d6128 read 9 October 2026. doi.org/10.1136/bmj.d6128
- Schulz KF, Altman DG, Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Annals of Internal Medicine. 2010;152:726-732. read 9 October 2026. care-statement.org
- Graf C, Battisti WP, Bridges D, Bruce-Winkler V, Conaty JM, Ellison JM, Field EA, Gurr JA, Marx M-E, Patel M, Sanes-Miller C, Yarker YE. Good publication practice for communicating company sponsored medical research: the GPP2 guidelines. BMJ. 2009;339:b4330. doi:10.1136/bmj.b4330 read 9 October 2026. doi.org/10.1136/bmj.b4330
- Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Medicine. 2009;6:e1000097. read 9 October 2026. care-statement.org
- Woloshin S, Schwartz LM, Casella SL, Kennedy AT, Larson RJ. Press releases by academic medical centers: not so academic? Annals of Internal Medicine. 2009;150:613-618. read 9 October 2026. archive.emwa.org
- Rothman DJ, McDonald WJ, Berkowitz CD, Chimonas SC, DeAngelis CD, Hale RW, et al. Professional medical associations and their relationships with industry: a proposal for controlling conflict of interest. JAMA. 2009;301(13):1367-1372. read 9 October 2026. equator-network.org
- Gotzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, et al. What should be done to tackle ghostwriting in the medical literature? PLoS Medicine. 2009;6(2):e1000023. read 9 October 2026. archive.emwa.org
- Hopewell S, Clarke M, Moher D, Wager E, Middleton P, Altman DG, Schulz KF; CONSORT Group. CONSORT for reporting randomized controlled trials in journal and conference abstracts: explanation and elaboration. PLoS Medicine. 2008;5:e20. read 9 October 2026. care-statement.org
- Ross JS, Hill KP, Egilman DS, Krumholz HM. Guest authorship and ghostwriting in publications related to rofecoxib: a case study of industry documents from rofecoxib litigation. JAMA. 2008;299:1800-1812. read 9 October 2026. archive.emwa.org
- Angell M. Industry-sponsored clinical research: a broken system. JAMA. 2008;300:1069-1071. read 9 October 2026. archive.emwa.org
- Titus SL, Wells JA, Rhoades LJ. Repairing research integrity. Nature. 2008;453:980-982. read 9 October 2026. archive.emwa.org
- Hill KP, Ross JS, Egilman DS, Krumholz HM. The ADVANTAGE seeding trial: a review of internal documents. Annals of Internal Medicine. 2008;149:251-258. read 9 October 2026. archive.emwa.org
- Norris R, Bowman A, Fagan JM, Gallagher ER, Geraci AB, Gertel A, et al. International Society for Medical Publication Professionals (ISMPP) position statement. Current Medical Research and Opinion. 2007;23:1837-1840. read 9 October 2026. archive.emwa.org
- von Elm E, Altman DG, Egger M, Pocock SJ, Gotzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ. 2007;335:806-808. read 9 October 2026. care-statement.org
- Jacobs A, Wager E. EMWA guidelines on the role of medical writers in developing peer-reviewed publications. Current Medical Research and Opinion. 2005;21:317-321. read 9 October 2026. archive.emwa.org
- Steinbrook R. Public registration of clinical trials. New England Journal of Medicine. 2004;351:315-317. doi:10.1056/NEJMp048191 read 9 October 2026. doi.org/10.1056/NEJMp048191
- Hamilton CW, Royer MG; AMWA 2002 Task Force on the Contributions of Medical Writers to Scientific Publications. AMWA position statement on the contributions of medical writers to scientific publications. AMWA Journal. 2003;18:13-16. read 9 October 2026. archive.emwa.org
- Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies. Current Medical Research and Opinion. 2003;19(3):149-154. doi:10.1185/030079903125001767 read 9 October 2026. doi.org/10.1185/030079903125001767
- Wager E, Field EA, Grossman L. Good publication practice for pharmaceutical companies: why we need another set of guidelines. Current Medical Research and Opinion. 2003;19(3):147-148. read 9 October 2026. ismpp.org
- Antes G, Chalmers I. Under-reporting of clinical trials is unethical. Lancet. 2003;361:978-979. read 9 October 2026. ismpp.org
- Davidoff F, DeAngelis CD, Drazen JM, Hoey J, Hojgaard L, Horton R, et al. Sponsorship, authorship, and accountability. Annals of Internal Medicine. 2001;135:463-466. read 9 October 2026. ismpp.org
- Rennie D, Flanagin A, Yank V. The contributions of authors. JAMA. 2000;284:89-91. read 9 October 2026. ismpp.org
- Stern JM, Simes RJ. Publication bias: evidence of delayed publication in a cohort study of clinical research papers. BMJ. 1997;315:640-645. read 9 October 2026. ismpp.org
- Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991;337:867-872. read 9 October 2026. ismpp.org
Every source above is a peer-reviewed article, a publisher’s record of one, or a standard issued by the body that owns it. Each carries the date it was last read. Where a standard moves, this article is revised rather than left up with a note.
How to cite this article
Pick your referencing style and copy it. Your university or target journal may vary the punctuation — check its guide if it has one.
Pubrica Academy. (2026, October 9). Organisational Adoption of Good Publication Practice (GPP): Procedures, Contracts and Approval Gates. Pubrica. https://pubrica.com/academy/concepts-definitions/viable-options-to-promote-gpp/
Pubrica Academy. “Organisational Adoption of Good Publication Practice (GPP): Procedures, Contracts and Approval Gates.” Pubrica, 9 Oct. 2026, pubrica.com/academy/concepts-definitions/viable-options-to-promote-gpp/.
Pubrica Academy (2026) Organisational Adoption of Good Publication Practice (GPP): Procedures, Contracts and Approval Gates. Pubrica. Available at: https://pubrica.com/academy/concepts-definitions/viable-options-to-promote-gpp/ (Accessed: 15 October 2026).
Pubrica Academy. “Organisational Adoption of Good Publication Practice (GPP): Procedures, Contracts and Approval Gates.” Pubrica. October 9, 2026. https://pubrica.com/academy/concepts-definitions/viable-options-to-promote-gpp/
Pubrica Academy, ‘Organisational Adoption of Good Publication Practice (GPP): Procedures, Contracts and Approval Gates’ (Pubrica, 9 October 2026) <https://pubrica.com/academy/concepts-definitions/viable-options-to-promote-gpp/> accessed 15 October 2026.
Pubrica Academy. Organisational Adoption of Good Publication Practice (GPP): Procedures, Contracts and Approval Gates. [Internet]. Pubrica; 2026 Oct 9 [cited 2026 Oct 15]. Available from: https://pubrica.com/academy/concepts-definitions/viable-options-to-promote-gpp/
Pubrica Academy, “Organisational Adoption of Good Publication Practice (GPP): Procedures, Contracts and Approval Gates,” Pubrica, Oct. 9, 2026. [Online]. Available: https://pubrica.com/academy/concepts-definitions/viable-options-to-promote-gpp/
@misc{viable_options_to_promote_gpp_2026,
author = {{Pubrica Academy}},
title = {Organisational Adoption of Good Publication Practice (GPP): Procedures, Contracts and Approval Gates},
howpublished = {Pubrica},
year = {2026},
month = {oct},
url = {https://pubrica.com/academy/concepts-definitions/viable-options-to-promote-gpp/},
note = {Accessed: <span data-cite-acc="iso">2026-10-15</span>}
}This article is written to be learned from. Cite it if you are referring to what it says; if you are using the evidence behind it, cite the sources listed above instead.
GPP adoption audit and gate specification
Part one establishes the organisation’s current position. Part two is a gate that can be applied to a publication immediately. Both should be kept short enough to be used — a gate that takes two weeks will be circumvented.
PART 1 - ADOPTION AUDIT (answer from documents, not from memory) Standard named in our publication SOP: ______________________ Standard and version named in our agency master agreement: ______________________ Standard named in investigator / CRO publication clauses: ______________________ Role that can stop a publication for GPP non-compliance: ______________________ Last time that happened: ______________________ Artefacts we can produce on request, for three recent publications: signed written agreement, dated before outline ...... 3 / 2 / 1 / 0 completed authorship grid, dated before drafting .... 3 / 2 / 1 / 0 acknowledgement permissions on file ................. 3 / 2 / 1 / 0 prior-disclosure inventory (abstracts, preprints) ... 3 / 2 / 1 / 0 reporting-guideline checklist ....................... 3 / 2 / 1 / 0 Completed studies in the portfolio with no publication plan: ______ PART 2 - GATE SPECIFICATION GATE 1 - BEFORE OUTLINING OR DRAFTING Approver (named role): ______________________ Evidence required, all filed in the publication record: [ ] Written agreement, signed by sponsor lead, lead author and agency, dated [ ] Authorship grid: every proposed author against every ICMJE criterion [ ] Acknowledgement list started, for everyone who failed a criterion [ ] Registration: registry, number, registration date, first enrolment date [ ] Place in the publication plan, and relationship to the primary report [ ] Reporting guideline identified for this design Decision: [ ] proceed [ ] hold, reason: ______________________ Waiver signed by: ______________________ (log every waiver) GATE 2 - BEFORE SUBMISSION Approver (named role): ______________________ Evidence required: [ ] Final authorship grid; any change from Gate 1 explained in writing [ ] Acknowledgement block complete: name, employer, role, funder, permission [ ] Sponsor-role statement covering design / conduct / analysis / decision [ ] Author data-access statement, at the level that is actually true [ ] Prior-disclosure inventory: congress abstracts, posters, preprints, DOIs [ ] Cross-reference to the primary report drafted into abstract and methods [ ] Reporting-guideline checklist completed [ ] Similarity report run and reviewed [ ] Data-availability statement names route, custodian, date, conditions Decision: [ ] submit [ ] hold, reason: ______________________ QUARTERLY GOVERNANCE REPORT (five metrics) 1. % with written agreement dated before outline ............ ____ 2. % with authorship grid before drafting / % changed after .. ____ / ____ 3. % of congress abstracts declaring writing support fully ... ____ 4. Gate waivers, with signers ................................ ____ 5. Completed studies with no publication plan ................ ____
Pubrica AcademyWritten and maintained by Pubrica’s subject matter experts. Articles are revised when the underlying standards change, and each article states the date on which it was last reviewed.
How Pubrica can help
Pubrica works to GPP as standard practice and states in writing the version to which its contribution is held and how that contribution will be declared. For organisations establishing their own adoption, Pubrica assists in drafting SOP clauses that generate filed artefacts and gate checklists that make them enforceable, and does not finalise an output in which its contribution cannot be declared.